Reproductive Health — MCQs
On this page
A 38-year-old woman with premature ovarian insufficiency diagnosed 2 years ago has been taking HRT (transdermal estradiol 100 mcg twice weekly with oral micronised progesterone 200 mg daily). She enquires about when she can discontinue HRT. She is otherwise well with no contraindications to HRT. What is the most appropriate advice regarding continuation of HRT?
According to the UK Medical Eligibility Criteria for Contraceptive Use (UKMEC), what category is assigned to the copper intrauterine device in a woman with current pelvic inflammatory disease?
A 53-year-old woman who underwent total hysterectomy for fibroids 8 years ago presents requesting HRT for severe hot flushes. She has a history of grade 1 endometrial cancer treated with hysterectomy alone 8 years ago, with no evidence of recurrence. She has no other significant medical history and her BMI is 26 kg/m². What is the most appropriate advice regarding HRT?
A 46-year-old woman with perimenopause presents with heavy menstrual bleeding and hot flushes. She has completed her family and requests contraception that will also manage her symptoms. She has a BMI of 32 kg/m², smokes 10 cigarettes daily, and has well-controlled hypertension on amlodipine. Pelvic examination is normal and recent pelvic ultrasound shows a bulky uterus with small fibroids (<3cm) but normal endometrium. What is the most appropriate management?
A 25-year-old woman presents requesting emergency contraception. She had unprotected sexual intercourse 72 hours ago and again 24 hours ago. She has a regular 28-day menstrual cycle and her last menstrual period started 11 days ago. Her BMI is 24 kg/m². She is not taking any regular medications. What is the most appropriate emergency contraception for this patient?
A 54-year-old woman presents for review 9 months after starting continuous combined HRT (oral estradiol 2 mg with dydrogesterone 10 mg). She reports good control of her vasomotor symptoms but has noticed persistent breast tenderness and mild bloating. Her BMI is 27 kg/m² and she has no history of breast disease. What is the most appropriate management to address her side effects while maintaining symptom control?
A 30-year-old woman attends for contraceptive counselling. She has a history of cervical intraepithelial neoplasia grade 2 (CIN2) treated successfully with large loop excision of the transformation zone 18 months ago. She is a non-smoker with a BMI of 25 kg/m² and has regular menstrual cycles. She requests long-acting reversible contraception. What is the most appropriate contraceptive method according to UK Medical Eligibility Criteria (UKMEC)?
A 50-year-old woman commenced sequential combined HRT (transdermal estradiol 50 mcg twice weekly with cyclical dydrogesterone 10 mg days 15-28) 9 months ago for perimenopausal symptoms. Her periods have been irregular with the last natural period 8 months ago before starting HRT. She now reports that her withdrawal bleeds on HRT are occurring on day 8-9 of progestogen therapy rather than after completion of the progestogen course. The bleeding is light and lasts 3-4 days. What is the most appropriate management?
A 32-year-old nulliparous woman who had a copper IUD inserted 3 years ago for long-term contraception now presents requesting removal as she is planning pregnancy in the next 6 months. She asks about what to expect regarding return to fertility. What is the most accurate information to provide about fertility after copper IUD removal?
A 55-year-old woman with a BMI of 35 kg/m² presents requesting HRT for moderate vasomotor symptoms. She has a history of well-controlled type 2 diabetes on metformin and hypertension managed with ramipril. Her blood pressure today is 142/88 mmHg. She underwent total abdominal hysterectomy for benign fibroids at age 47. Her mother had a deep vein thrombosis at age 72 following hip replacement surgery. What is the most appropriate HRT regimen to initiate?
Reproductive Health UK Medical PG Practice Questions and MCQs
Question 21: A 38-year-old woman with premature ovarian insufficiency diagnosed 2 years ago has been taking HRT (transdermal estradiol 100 mcg twice weekly with oral micronised progesterone 200 mg daily). She enquires about when she can discontinue HRT. She is otherwise well with no contraindications to HRT. What is the most appropriate advice regarding continuation of HRT?
- A. Continue HRT at least until age 45 years
- B. Continue HRT until age 51 years (average age of natural menopause) (Correct Answer)
- C. Continue HRT for 5 years from diagnosis then review
- D. Continue HRT until age 50 years then switch to lower dose
- E. Discontinue HRT now as she has been on it for 2 years
Explanation: ***Continue HRT until age 51 years (average age of natural menopause)***- In women with **premature ovarian insufficiency (POI)**, HRT is recommended until at least the **average age of natural menopause** (51 years) to reduce long-term health risks.- This duration is crucial for maintaining **bone mineral density** and reducing the risk of **cardiovascular disease** and cognitive decline associated with early estrogen deficiency.*Continue HRT at least until age 45 years*- While 45 marks the end of "early menopause," it is still significantly younger than the **average age of natural menopause**.- Discontinuing at 45 would leave the patient with a deficit of **estrogen protection** during years when she would naturally still be premenopausal.*Continue HRT for 5 years from diagnosis then review*- The **five-year review** rule often applied to older postmenopausal women does not apply to POI patients who are replacing a **physiological deficiency**.- Treatment should be viewed as **hormone replacement** to match natural biological timing rather than a short-term symptom management strategy.*Continue HRT until age 50 years then switch to lower dose*- There is no clinical requirement to automatically **switch to a lower dose** at 50, as the goal is to align with the natural transition to menopause.- Management should be individualized at the **age of natural menopause**, but mandated dose reduction before this point is not standard practice for POI.*Discontinue HRT now as she has been on it for 2 years*- Discontinuing after only 2 years would expose a 40-year-old woman to high risks of **osteoporosis** and **urogenital atrophy**.- Short-term use is insufficient for **POI management**, as these patients require hormonal support until they reach the physiological age of menopause.
Question 22: According to the UK Medical Eligibility Criteria for Contraceptive Use (UKMEC), what category is assigned to the copper intrauterine device in a woman with current pelvic inflammatory disease?
- A. UKMEC 1 - No restriction for use
- B. UKMEC 2 - Advantages generally outweigh risks
- C. UKMEC 3 - Risks usually outweigh advantages
- D. UKMEC 4 - Unacceptable health risk (Correct Answer)
- E. UKMEC 2 for insertion, UKMEC 1 for continuation
Explanation: ***UKMEC 4 - Unacceptable health risk***- For a woman with **current pelvic inflammatory disease (PID)**, the insertion of a copper IUD is classified as **UKMEC 4**, indicating an unacceptable health risk due to the potential for worsening the infection.- The procedure could facilitate the **migration of pathogens** from the lower to the upper genital tract, increasing the risk of complications such as **tubo-ovarian abscesses** and subsequent infertility.*UKMEC 1 - No restriction for use*- This category applies to conditions where there is no restriction for use, such as a **past history of PID** followed by a successful pregnancy.- Current PID represents an active **contraindication** and does not fall into this risk-free category.*UKMEC 2 - Advantages generally outweigh risks*- **UKMEC 2** would apply to a past history of PID without a subsequent pregnancy, but not to an **acute infection**.- For active PID, the risks of **ascending infection** far outweigh any benefits of immediate IUD insertion.*UKMEC 3 - Risks usually outweigh advantages*- This category is reserved for conditions where risks generally outweigh benefits but the method is not strictly prohibited; current PID is more severe, warranting a **complete restriction (Category 4)**.- It is often confused with clinical scenarios like **unexplained vaginal bleeding** before evaluation, which is a Category 3 for copper IUDs.*UKMEC 2 for insertion, UKMEC 1 for continuation*- This distinction is incorrect for current PID; in fact, the classification is **UKMEC 4 for insertion** and **UKMEC 2 for continuation** if the device is already in place and the patient responds to treatment.- If a patient develops PID with an IUD *in situ*, the device does not necessarily need removal if **antibiotic therapy** is initiated and the patient is closely monitored.
Question 23: A 53-year-old woman who underwent total hysterectomy for fibroids 8 years ago presents requesting HRT for severe hot flushes. She has a history of grade 1 endometrial cancer treated with hysterectomy alone 8 years ago, with no evidence of recurrence. She has no other significant medical history and her BMI is 26 kg/m². What is the most appropriate advice regarding HRT?
- A. HRT is contraindicated due to her history of endometrial cancer (Correct Answer)
- B. Prescribe estrogen-only HRT (transdermal estradiol) as she has had hysterectomy
- C. Prescribe continuous combined HRT despite hysterectomy due to cancer history
- D. Recommend selective serotonin reuptake inhibitors as first-line treatment
- E. Prescribe tibolone as an alternative to standard HRT
Explanation: ***HRT is contraindicated due to her history of endometrial cancer*** - A personal history of **estrogen-sensitive endometrial cancer** is an absolute contraindication to hormone replacement therapy, as exogenous estrogen could stimulate any **residual malignant cells**. - This contraindication applies even after a complete hysterectomy, regardless of the **grade of cancer**, the time elapsed since treatment (8 years), or the absence of current recurrence. *Prescribe estrogen-only HRT (transdermal estradiol) as she has had hysterectomy* - While **estrogen-only HRT** is typically prescribed for women post-hysterectomy, it is unsafe in this patient due to her history of **estrogen-dependent endometrial cancer**. - Providing estrogen, even transdermally, carries a significant risk of stimulating potential **dormant malignant cells** elsewhere in the body. *Prescribe continuous combined HRT despite hysterectomy due to cancer history* - Continuous combined HRT is intended to protect the **endometrium** from estrogenic stimulation by adding a progestogen, which is irrelevant in a patient who has undergone a **total hysterectomy**. - The primary concern remains the history of **estrogen-sensitive cancer**, which contraindicates any form of estrogenic therapy, whether combined or alone. *Recommend selective serotonin reuptake inhibitors as first-line treatment* - While **SSRIs** (e.g., paroxetine, escitalopram) or **SNRIs** (e.g., venlafaxine) are valid non-hormonal alternatives for managing vasomotor symptoms, the most appropriate initial advice is to identify and communicate the absolute **contraindication to HRT**. - Recommending an alternative treatment does not address the fundamental safety issue regarding hormonal therapy in this patient's specific medical history. *Prescribe tibolone as an alternative to standard HRT* - **Tibolone** is a synthetic steroid with estrogenic, progestogenic, and androgenic properties, and it is contraindicated in women with a history of **estrogen-dependent cancers**. - Its estrogenic effects mean it carries the same risk as conventional HRT for stimulating residual or recurrent **endometrial cancer cells**.
Question 24: A 46-year-old woman with perimenopause presents with heavy menstrual bleeding and hot flushes. She has completed her family and requests contraception that will also manage her symptoms. She has a BMI of 32 kg/m², smokes 10 cigarettes daily, and has well-controlled hypertension on amlodipine. Pelvic examination is normal and recent pelvic ultrasound shows a bulky uterus with small fibroids (<3cm) but normal endometrium. What is the most appropriate management?
- A. Combined oral contraceptive pill containing 30 mcg ethinylestradiol
- B. 52 mg levonorgestrel intrauterine system (Correct Answer)
- C. Oral norethisterone 5 mg three times daily days 5-26
- D. Progestogen-only pill (desogestrel 75 mcg)
- E. Tranexamic acid 1 g three times daily during menstruation
Explanation: ***52 mg levonorgestrel intrauterine system***- The **LNG-IUS** is the first-line treatment for **heavy menstrual bleeding** and provides highly effective **contraception**, which the patient specifically requested.- It is safe for this patient (UKMEC 1) despite her high BMI, **smoking status**, and **hypertension**, and it can later serve as the progestogen component of **HRT** for perimenopausal symptoms.*Combined oral contraceptive pill containing 30 mcg ethinylestradiol*- This option is contraindicated (**UKMEC 3/4**) because the patient is over 35 years old and **smokes**, which significantly increases the risk of **venous thromboembolism** and stroke.- Her **hypertension** further increases the cardiovascular risks associated with ethinylestradiol, making combined hormonal methods unsuitable.*Oral norethisterone 5 mg three times daily days 5-26*- While high-dose oral progestogens can manage bleeding, they are less effective than the **LNG-IUS** and require strict **daily compliance**.- This regimen does not provide reliable **contraception** and often has more systemic side effects compared to local intrauterine delivery.*Progestogen-only pill (desogestrel 75 mcg)*- The **POP** provides effective contraception and is safe for smokers with hypertension, but it is not a primary treatment for **heavy menstrual bleeding** in this context.- It may cause **irregular bleeding** or spotting rather than the significant reduction in menstrual volume needed to manage her symptoms, and does not directly address hot flushes.*Tranexamic acid 1 g three times daily during menstruation*- This is a non-hormonal treatment that effectively reduces **menstrual blood loss**, but it provides no **contraceptive benefit**.- It does not address the patient's **hot flushes** or her specific request for a contraceptive method.
Question 25: A 25-year-old woman presents requesting emergency contraception. She had unprotected sexual intercourse 72 hours ago and again 24 hours ago. She has a regular 28-day menstrual cycle and her last menstrual period started 11 days ago. Her BMI is 24 kg/m². She is not taking any regular medications. What is the most appropriate emergency contraception for this patient?
- A. Levonorgestrel 1.5 mg single dose
- B. Ulipristal acetate 30 mg single dose
- C. Copper intrauterine device (Correct Answer)
- D. Levonorgestrel 3 mg single dose (double dose)
- E. Combined oral contraceptive (Yuzpe regimen)
Explanation: ***Copper intrauterine device*** - The **copper IUD** is the most effective method of emergency contraception (EC) with over **99% efficacy**, and it can be inserted up to **5 days** after the earliest episode of unprotected sex or 5 days after the earliest predicted **ovulation**. - This patient is on **day 11** of a 28-day cycle, placing her in the high-risk **peri-ovulatory** window; the IUD is the only method that provides **ongoing contraception** and works effectively even after fertilization by preventing implantation. *Levonorgestrel 1.5 mg single dose* - This hormonal method primarily works by **delaying ovulation** and is significantly less effective if the **LH surge** has already begun, which is likely on day 11 of a regular cycle. - It is generally licensed up to **72 hours** after unprotected intercourse, and its efficacy decreases notably the later it is administered compared to the copper IUD. *Ulipristal acetate 30 mg single dose* - While more effective than levonorgestrel and licensed for use up to **120 hours** (5 days), it is still less effective than the **copper IUD** in the crucial peri-ovulatory period. - It works by delaying ovulation even after the **LH surge** has started (but before it peaks), but its efficacy is diminished if ovulation has fully occurred or fertilization has already taken place. *Levonorgestrel 3 mg single dose (double dose)* - A double dose of levonorgestrel (3 mg) is typically recommended only for women with a **BMI >26 kg/m²** or weight >70kg, or those taking **enzyme-inducing** medications. - This patient has a **BMI of 24 kg/m²**, so a double dose is not clinically indicated and would not provide superior efficacy compared to the standard dose or the copper IUD. *Combined oral contraceptive (Yuzpe regimen)* - The **Yuzpe regimen** is an older and significantly **less effective** method of emergency contraception compared to newer hormonal options and the copper IUD. - It is associated with a much higher incidence of **side effects** such as nausea and vomiting due to the high estrogen content, making it a less preferred option.
Question 26: A 54-year-old woman presents for review 9 months after starting continuous combined HRT (oral estradiol 2 mg with dydrogesterone 10 mg). She reports good control of her vasomotor symptoms but has noticed persistent breast tenderness and mild bloating. Her BMI is 27 kg/m² and she has no history of breast disease. What is the most appropriate management to address her side effects while maintaining symptom control?
- A. Switch to sequential combined HRT regimen
- B. Reduce the estradiol dose to 1 mg daily with the same progestogen
- C. Switch to transdermal estradiol with micronised progesterone (Correct Answer)
- D. Add evening primrose oil and continue current HRT
- E. Switch to estradiol with norethisterone acetate
Explanation: ***Switch to transdermal estradiol with micronised progesterone*** - **Transdermal estradiol** avoids first-pass hepatic metabolism, potentially leading to fewer systemic side effects like **breast tenderness** due to more stable hormone levels. - **Micronised progesterone** is a body-identical progestogen often associated with a lower incidence of typical progestogenic side effects, such as **bloating** and mastalgia, compared to synthetic progestogens like dydrogesterone. *Switch to sequential combined HRT regimen* - Switching to a **sequential regimen** would reintroduce cyclical withdrawal bleeding, which is generally undesirable for a 54-year-old woman already established on continuous combined HRT and likely postmenopausal. - This change would not directly address the specific side effects of **breast tenderness** (often estrogen-related) or **bloating** (often progestogen-related) as effectively as modifying the type or route of hormones. *Reduce the estradiol dose to 1 mg daily with the same progestogen* - The patient reports good control of her **vasomotor symptoms** on the current 2 mg estradiol dose; reducing it risks a return of these symptoms. - This approach would also fail to address the **progestogenic side effects** (bloating) potentially caused by dydrogesterone, which is a significant part of her complaint. *Add evening primrose oil and continue current HRT* - **Evening primrose oil** lacks robust scientific evidence to support its effectiveness in significantly alleviating HRT-induced breast tenderness or systemic bloating. - The most appropriate management involves optimizing the **hormone therapy itself** rather than adding unproven supplements, especially when direct adjustments to HRT can be made. *Switch to estradiol with norethisterone acetate* - **Norethisterone acetate** is a synthetic progestogen that is generally more **androgenic** and can be associated with a higher incidence of progestogenic side effects like **bloating**, mood changes, and breast tenderness. - Therefore, switching to this progestogen is unlikely to resolve her current complaints and may even worsen them, as it is not typically better tolerated than dydrogesterone for these specific side effects.
Question 27: A 30-year-old woman attends for contraceptive counselling. She has a history of cervical intraepithelial neoplasia grade 2 (CIN2) treated successfully with large loop excision of the transformation zone 18 months ago. She is a non-smoker with a BMI of 25 kg/m² and has regular menstrual cycles. She requests long-acting reversible contraception. What is the most appropriate contraceptive method according to UK Medical Eligibility Criteria (UKMEC)?
- A. Combined oral contraceptive pill
- B. Levonorgestrel intrauterine system
- C. Copper intrauterine device
- D. Progestogen-only implant (Correct Answer)
- E. Depo-medroxyprogesterone acetate injection
Explanation: ***Progestogen-only implant*** - The **progestogen-only implant** is classified as **UKMEC 1** (no restriction) for patients with a history of successfully treated **CIN2**, making it a highly appropriate LARC choice. - It provides the highest contraceptive efficacy (>99%) and does not carry the theoretical local tissue concerns associated with some intrauterine methods in the context of cervical dysplasia. *Combined oral contraceptive pill* - While effective, this is not a **Long-Acting Reversible Contraceptive (LARC)**, which was specifically requested by the patient. - According to **UKMEC** guidelines, combined hormonal methods are categorized as **UKMEC 2** for cervical intraepithelial neoplasia, unlike the implant which is MEC 1. *Levonorgestrel intrauterine system* - The **LNG-IUS** is classified as **UKMEC 2** for women with cervical neoplasia awaiting treatment or with recent treatment, as the theoretical risks of local progestogen on the cervix generally outweigh the benefits. - Although it is a **LARC**, the higher MEC category compared to the implant makes it a less ideal choice in this specific scenario. *Copper intrauterine device* - The **Copper IUD** is classified as **UKMEC 1** and is a valid LARC; however, the implant remains a primary recommendation for its superior efficacy and lack of procedure-related cervical irritation. - Unlike the implant, the Copper IUD may cause **increased menstrual bleeding** or pain, which may not be desirable given her regular cycles. *Depo-medroxyprogesterone acetate injection* - The **DMPA injection** is a **UKMEC 1** method for this patient, but it is often considered a "medium-acting" method rather than a long-term LARC like the implant or IUDs. - It requires administration every **12 weeks**, whereas the implant provides protection for **3 years**, aligning better with the request for LARC.
Question 28: A 50-year-old woman commenced sequential combined HRT (transdermal estradiol 50 mcg twice weekly with cyclical dydrogesterone 10 mg days 15-28) 9 months ago for perimenopausal symptoms. Her periods have been irregular with the last natural period 8 months ago before starting HRT. She now reports that her withdrawal bleeds on HRT are occurring on day 8-9 of progestogen therapy rather than after completion of the progestogen course. The bleeding is light and lasts 3-4 days. What is the most appropriate management?
- A. Urgent transvaginal ultrasound and endometrial assessment for early breakthrough bleeding
- B. Increase the progestogen dose to dydrogesterone 20 mg to improve endometrial stability
- C. Continue current regimen as irregular bleeding patterns can occur in the first year of sequential HRT
- D. Switch to continuous combined HRT as she is likely postmenopausal (Correct Answer)
- E. Add additional cyclical progestogen in the first half of the cycle
Explanation: ***Switch to continuous combined HRT as she is likely postmenopausal*** - The occurrence of **withdrawal bleeds on day 8-9 of progestogen therapy** (before completion of the course) suggests the patient's own endogenous estrogen levels are waning, indicating a transition towards **postmenopause**. - Given her age (50) and that her last natural period was 8 months ago, she is likely approaching the 12-month **amenorrhea threshold** for postmenopause, making **continuous combined HRT** (which aims for no cyclical bleeding) the most appropriate next step. *Urgent transvaginal ultrasound and endometrial assessment for early breakthrough bleeding* - **Urgent endometrial investigation** is typically indicated for unscheduled bleeding in a patient *established* on HRT for more than 6-12 months, or for new-onset postmenopausal bleeding. - This specific pattern of **early withdrawal bleeding** on sequential HRT, especially with a natural period 8 months ago, is more indicative of a physiological transition rather than immediate **endometrial pathology**. *Increase the progestogen dose to dydrogesterone 20 mg to improve endometrial stability* - Increasing the **progestogen dose** is usually considered when bleeding is **heavy** or occurs *late* in the progestogen phase, indicating insufficient endometrial suppression. - It would not address **early withdrawal bleeding**, which points to a different physiological shift (waning endogenous estrogen and thus an earlier 'withdrawal' from external progestogen due to lack of endogenous estrogen priming). *Continue current regimen as irregular bleeding patterns can occur in the first year of sequential HRT* - While some irregular bleeding can occur, an **early withdrawal bleed** (bleeding while still taking progestogen) is a specific sign that the sequential regimen is no longer synchronized with her changing endogenous hormone levels. - Ignoring this pattern can lead to patient dissatisfaction and may delay appropriate management for her menopausal stage. *Add additional cyclical progestogen in the first half of the cycle* - Adding progestogen in the first half of the cycle (the estrogen-only phase) would fundamentally alter the sequential nature of the HRT, potentially leading to a more continuous progestogen exposure. - This is not a standard or appropriate management strategy for early withdrawal bleeding in sequential HRT and could further complicate bleeding patterns.
Question 29: A 32-year-old nulliparous woman who had a copper IUD inserted 3 years ago for long-term contraception now presents requesting removal as she is planning pregnancy in the next 6 months. She asks about what to expect regarding return to fertility. What is the most accurate information to provide about fertility after copper IUD removal?
- A. Fertility returns to baseline immediately after removal with no delay in conception rates (Correct Answer)
- B. There is typically a 3-6 month delay in return to normal fertility after IUD removal
- C. Copper IUDs may cause permanent reduction in fertility in nulliparous women
- D. The duration of IUD use (3 years) will result in at least 3 months of reduced fertility
- E. Fertility is reduced for 1-2 cycles after removal due to endometrial changes
Explanation: ***Fertility returns to baseline immediately after removal with no delay in conception rates*** - The **copper IUD** works primarily by preventing fertilization through a **local inflammatory response** that is rapidly reversible upon removal. - Studies consistently show that **conception rates** after copper IUD removal are similar to those of women discontinuing non-hormonal contraception or having no prior contraception. *There is typically a 3-6 month delay in return to normal fertility after IUD removal* - This delay is characteristic of **hormonal methods** like **Depot medroxyprogesterone acetate (DMPA)**, which suppress ovulation and require a washout period. - The **copper IUD** does not affect the **hypothalamic-pituitary-ovarian axis** or ovulation, so no such delay is expected. *Copper IUDs may cause permanent reduction in fertility in nulliparous women* - Modern evidence refutes this misconception; **copper IUDs** do not cause **infertility** or **tubal damage** in women at low risk for sexually transmitted infections. - The historical link to **pelvic inflammatory disease (PID)** and subsequent infertility was largely associated with older IUD designs and STI exposure, not the device itself. *The duration of IUD use (3 years) will result in at least 3 months of reduced fertility* - The **duration of copper IUD use** does not influence the time to return to fertility; its mechanism is local and immediately reversible. - Fertility is not diminished by the length of time the IUD is in place, whether for a few months or several years. *Fertility is reduced for 1-2 cycles after removal due to endometrial changes* - The **endometrial changes** induced by the copper IUD (e.g., sterile inflammation) resolve very quickly after removal. - The uterus becomes receptive to **implantation** almost immediately, with no clinically significant period of reduced fertility due to endometrial recovery.
Question 30: A 55-year-old woman with a BMI of 35 kg/m² presents requesting HRT for moderate vasomotor symptoms. She has a history of well-controlled type 2 diabetes on metformin and hypertension managed with ramipril. Her blood pressure today is 142/88 mmHg. She underwent total abdominal hysterectomy for benign fibroids at age 47. Her mother had a deep vein thrombosis at age 72 following hip replacement surgery. What is the most appropriate HRT regimen to initiate?
- A. Transdermal estradiol patches 50 mcg twice weekly without progestogen (Correct Answer)
- B. Oral estradiol 2 mg daily with micronized progesterone 200 mg daily
- C. Transdermal estradiol patches 25 mcg twice weekly with levonorgestrel IUS for endometrial protection
- D. Tibolone 2.5 mg daily as a single agent
- E. Oral conjugated equine estrogens 0.625 mg daily without progestogen
Explanation: ***Transdermal estradiol patches 50 mcg twice weekly without progestogen*** - Since the patient has undergone a **total abdominal hysterectomy**, she only requires **estrogen-only HRT**; progestogen for endometrial protection is unnecessary. - The **transdermal route** is safer for patients with **obesity (BMI 35)**, **hypertension**, and **diabetes** because it avoids first-pass hepatic metabolism, minimizing the risk of **venous thromboembolism (VTE)** and metabolic interference. *Oral estradiol 2 mg daily with micronized progesterone 200 mg daily* - Combined HRT containing **progesterone** is not indicated for a woman without a uterus and unnecessarily increases risks such as breast cancer relative to estrogen-only therapy. - **Oral estrogen** confers a higher risk of **VTE** and gallbladder disease compared to transdermal delivery, especially in an obese patient with additional cardiovascular risk factors. *Transdermal estradiol patches 25 mcg twice weekly with levonorgestrel IUS for endometrial protection* - Endometrial protection via a **levonorgestrel IUS** is redundant and inappropriate for a patient who has had a **hysterectomy**. - While the transdermal delivery is correct, the addition of a progestogen adds unnecessary side effects and costs for this specific patient. *Tibolone 2.5 mg daily as a single agent* - **Tibolone** is a synthetic steroid with estrogenic, progestogenic, and androgenic properties; while it can be used in post-hysterectomy women, its **VTE risk profile** makes it a less preferred first-line option compared to transdermal estradiol in a patient with multiple risk factors. - Although it is a single-agent option, **transdermal estradiol** is generally favored in patients with cardiovascular risk factors due to its more favorable VTE and metabolic profile. *Oral conjugated equine estrogens 0.625 mg daily without progestogen* - While this provides estrogen-only therapy, the **oral route** significantly increases the production of clotting factors in the liver, raising **VTE risk**. - **Transdermal patches** are the clinical gold standard for women with co-morbidities like **Type 2 Diabetes** and **hypertension** to maintain stable estrogen levels with minimal metabolic impact.
Practice by Chapter
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free